LS&HC Horizons 2022 - Flipbook - Page 35
6
Transactions
Unique issues in cell and gene therapy transactions
36
Application of ‘commercially reasonable efforts’ to
life sciences transactions and disputes
37
Using CVRs to bridge valuation gaps in life sciences
M&A transactions
38
Arbitrating post-M&A disputes in life sciences
39
